BioTech IQ

An interview with John Glasspool, CEO of Anthos Therapeutics. Did you know that VTE is the 2nd leading cause of death in cancer patients after the cancer itself? Did you know that many patients choose not to us the current standard of care to blood clotting due to excessive bleeding? Anthos Therapeutics is addressing this major unmet medical need in thromboembolic events with their lead candidate abelacimab. Abelacimab is an investigational monoclonal antibody that achieves profound suppression of the novel antithrombotic target Factor XI.

https://anthostherapeutics.com/
https://thebiotechiqpodcast.com/

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/

This episode of BioTech IQ features Kleanthis Xanthopoulos, Ph.D. He is the co-founder, chairman of the board, and CEO of Shoreline Biosciences. As part of our "What's Ahead in Biotech: #2022" series Kleanthis talks about the power of induced pluripotent stem cells (iPSC) derived NK cells,  and macrophage immunotherapies. What is the future of immunotherapies? Listen and find out!

https://shorelinebio.com/

https://thebiotechiqpodcast.com/

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/

Tom shares with us some of his journey and how that led him to co-found Biomea Fusion. We discuss some of the science behind irreversible drugs and covalent bonding. Using their fusion system there is greater potential for high selectivity, deep inactivation of target, and a greater therapeutic window.

https://biomeafusion.com/
https://thebiotechiqpodcast.com/podcast/

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/

CliniStart launched to provide innovative tech-enabled solutions focused on global investigator contracts, budgets, and payments. And they did all of this just as the COVID-19 pandemic was hitting. This gave them an opportunity to shift and adapt. In this episode we address the challenges causing friction at during clinical trial start-up and what it takes to launch a start-up company.

https://clinistart.com/

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/

On this episode we have Brenda Sousa, previously the Chief Human Resources Officer with Constellation Pharmaceuticals. Brenda shares with us part of her backstory and entry into the world of Biotech. We discuss people, culture, the function of HR, and how the industry requires a unique yet similar approach. Ammon also shares past experiences with Brenda and gets her take on them.

#BiotechIQ #Biotech #Drugdevelopment #Recruiting #Staffing

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/

In this episode of BioTech IQ Ammon interviews Stewart Hallet the COO of SFJ Pharmaceuticals, a specialty pharmaceutical company with a unique business model. The discussion touches on a number of things in clinical operations including working with CROs, leadership, and resourcing. 



#BioTechIQ #ClinicalOperations #DrugDevelopment #Podcasts

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/

Co-founders Shawn Carbonell and Brent Witgen discuss the progress of the 1st cohort (BRZN1) as they are well into the Brazen Bio program. We also get the chance to interview one of the founders currently in the program. We discuss what he is working on and what his experience has been in the program. Do you have a project that needs acceleration? Then don't hesitate, go to brazen.bio and get your application in for the next cohort.

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/

Kathleen shares fantastic insights on understanding behavioral psychology and how it applies to successful clinical trials. We had a great conversation that touched on increasing diversity in trials to understanding our own behavior and how we can potentially understand patients better. This can be applied in a way to close the gap between intention and action. Kathleen co-authored a Book called "Why We Resist: The Surprising Truths about Behavior Change: A Guidebook for Healthcare Communicators, Advocates and Change Agents" You can check it out at the link below. PSA: I have no sponsorships or financial agreements to promote the book. I figured since I read it and talked about it on the show people might want to check it out.

https://www.amazon.com/Why-Resist-Surprising-Healthcare-Communicators/dp/057854766X

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/

Seth Lederman is the CEO of Tonix Pharmaceuticals and a physician scientist with a two decades of research experience. Prior to becoming an entrepreneur, he was an Associate Professor at Columbia University. Dr. Lederman’s groundbreaking research led to the discovery of the CD-40 ligand and its role in T cell helper function. Currently, Dr. Lederman oversees Tonix Pharmaceuticals and its diverse programs that are aimed to develop therapeutics for chronic CNS and immunologic conditions, that include indications like fibromyalgia, Covid-19 and Long Covid, amongst others. Dr. Lederman earned an AB from Princeton University in Chemistry and an MD from Columbia University's College of Physicians and Surgeons. Dr. Lederman trained in internal medicine and rheumatology at Columbia's Presbyterian Hospital.

https://www.tonixpharma.com/

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/

Doug Looker is the VP of Operations with Validus Cellular Therapeutics. Validus is using cellular therapy to target infections by fighting the biology of antimicrobial resistance by activating the biology of the mammalian immune system. Doug walks us the through the process of establishing the CMC process that will drive success at every stage of the clinical trial process. And we have a brief discussion on animals being used in trials.

During the recording and editing of this episode Doug was the VP of Preclinical Development and Manufacturing at Amicrobe, Inc. Therefore the intro does not reflect his currrent position.

https://validustherapeutics.com/

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/